{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:38:00Z","timestamp":1782139080408,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jns.2024.123303","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T23:14:37Z","timestamp":1731280477000},"page":"123303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"467","author":[{"given":"Sergey A.","family":"Kornilov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Brunkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Gervasi-Follmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Winger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Aldershoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lausted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Troisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Repovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Magis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0005","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207291120","article-title":"Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity","volume":"120","author":"Shinoda","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2024.123303_bb0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221544120","article-title":"Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy","volume":"120","author":"Heming","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"41","key":"10.1016\/j.jns.2024.123303_bb0020","doi-asserted-by":"crossref","first-page":"25690","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis","volume":"117","author":"Nissimov","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.jns.2024.123303_bb0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jns.2024.123303_bb0030","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.jns.2024.123303_bb0035","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000008189","article-title":"Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis","volume":"93","author":"Barkhof","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acn3.51732","article-title":"Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1148\/radiol.211528","article-title":"Joint MRI T1 Unenhancing and contrast-enhancing multiple sclerosis lesion segmentation with deep learning in OPERA trials","volume":"302","author":"Krishnan","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jns.2024.123303_bb0050","first-page":"93","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","author":"Bar-Or","year":"2023","journal-title":"eBioMedicine"},{"issue":"1","key":"10.1016\/j.jns.2024.123303_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010012","article-title":"Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients","volume":"8","author":"Gingele","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jns.2024.123303_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200084","article-title":"Ocrelizumab impairs the phenotype and function of memory CD8+ T cells","volume":"10","author":"Mathias","year":"2023","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jns.2024.123303_bb0065","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000940","article-title":"Effect of Ocrelizumab in blood leukocytes of patients with primary progressive MS","volume":"8","author":"Fern\u00e1ndez-Velasco","year":"2021","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200091","article-title":"Immune profiling reveals the T-cell effect of Ocrelizumab in early relapsing-remitting multiple sclerosis","volume":"10","author":"Garcia","year":"2023","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2024.123303_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.578008","article-title":"Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS)","volume":"374","author":"Curran","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2024.123303_bb0080","first-page":"14","article-title":"Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles","author":"Fong","year":"2023","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123303_bb0085","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200083","article-title":"Ocrelizumab treatment modulates B-cell regulating factors in multiple sclerosis","volume":"10","author":"Ho","year":"2023","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"22","key":"10.1016\/j.jns.2024.123303_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213759","article-title":"Acute effects of Ocrelizumab infusion in multiple sclerosis patients","volume":"23","author":"Akg\u00fcn","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0095","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/biology12040587","article-title":"Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-treated pwMS and infectious risk","volume":"12","author":"Zingaropoli","year":"2023","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0100","article-title":"Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a","volume":"5","author":"MacMillan","year":"2019","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol."},{"issue":"737","key":"10.1016\/j.jns.2024.123303_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi0295","article-title":"B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans","volume":"16","author":"Wang","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2024.123303_bb0115","first-page":"76","article-title":"Alterations of host-gut microbiome interactions in multiple sclerosis","author":"Cantoni","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jns.2024.123303_bb0120","series-title":"Serum proteomic profiles of UK Biobank participants with Multiple Sclerosis","author":"Jacobs","year":"2023"},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab240","article-title":"Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach","volume":"3","author":"Yeo","year":"2021","journal-title":"Brain Commun."},{"issue":"25","key":"10.1016\/j.jns.2024.123303_bb0130","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2123265119","article-title":"Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target","volume":"119","author":"Zahoor","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"14","key":"10.1016\/j.jns.2024.123303_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147592","article-title":"Sphingolipid catabolism and Glycerophospholipid levels are altered in erythrocytes and plasma from multiple sclerosis patients","volume":"23","author":"Momchilova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2024.123303_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47906-x","article-title":"Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis","volume":"9","author":"Nogueras","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0145","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1471-4159.2012.07934.x","article-title":"Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism","volume":"123","author":"Gonzalo","year":"2012","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.jns.2024.123303_bb0150","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3324\/haematol.2019.219519","article-title":"Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction","volume":"105","author":"Kooij","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0155","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/acn3.51004","article-title":"Gut microbiome variation is associated to multiple sclerosis phenotypic subtypes","volume":"7","author":"Reynders","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202200018","article-title":"Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis","volume":"17","author":"Qureshi","year":"2023","journal-title":"PROTEOMICS \u2013 Clin. Appl."},{"key":"10.1016\/j.jns.2024.123303_bb0165","first-page":"20","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","author":"Wik","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/14622416.9.4.383","article-title":"Analysis of the adult human plasma metabolome","volume":"9","author":"Lawton","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.jns.2024.123303_bb0175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","article-title":"MissForest\u2014non-parametric missing value imputation for mixed-type data","volume":"28","author":"Stekhoven","year":"2012","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.jns.2024.123303_bb0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12859-022-04828-2","article-title":"Orsum: a Python package for filtering and comparing enrichment analyses using a simple principle","volume":"23","author":"Ozisik","year":"2022","journal-title":"BMC Bioinform."},{"issue":"4","key":"10.1016\/j.jns.2024.123303_bb0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","article-title":"Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology","volume":"3","author":"Chu","year":"2022","journal-title":"Nat. Can."},{"issue":"3","key":"10.1016\/j.jns.2024.123303_bb0190","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.medj.2021.01.006","article-title":"Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis","volume":"2","author":"Kaufmann","year":"2021","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.jns.2024.123303_bb0195","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1038\/s41467-023-42682-9","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"\u00c5kesson","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T09:24:59Z","timestamp":1733909099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24004398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"alternative-id":["S0022510X24004398"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123303","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123303"}}